infusions. 2 Although there are intra-and interindividual variances, on average, standard rFVIII has a plasma half-life of ~12 hours and requires approximately 3 to 4 infusions per week for effective prophylaxis. 3 Lack of adherence to FVIII prophylaxis is a key determinant of increased bleeding. 2 Therefore, as only a few haemarthroses can have a debilitating impact, 4 strict adherence to bleed prevention regimens is important for preservation of joint function. 2 To address the burden of frequent prophylactic rFVIII infusions, several rFVIII products have been designed to improve their pharmacokinetics (PKs) properties. 5 Prophylaxis with an extended half-life (EHL) rFVIII replacement therapy with correspondingly longer intervals between doses has the potential to reduce the burden of infusions and/or achieve higher FVIII trough levels. 6 Recently, many new rFVIII products have entered the market, including some with PK characteristics that have evolved as a result of other enhancements made to the parent compound (such as manufacturing improvements). Regulatoryapproved dosing regimens for new rFVIII products do not differentiate standard from EHL. Some products list a dosing frequency range that includes both standard (3+ weekly infusions) and extended dosing (2 weekly infusions). [7] [8] [9] In the clinical studies on which these dosing recommendations are based, approximately one-third of participants had twice weekly dosing, while the rest had shorter dosing intervals. 7, 9 Ideally, an EHL rFVIII should allow reduced dosing frequency with retention of haemostatic efficacy compared to standard half-life rFVIII for the majority of patients. The current literature also does not provide clarity on what constitutes an EHL rFVIII product. Some authors conclude that rFVIII products have enhanced PK properties based on absolute half-lives that are higher than average standard rFVIIIs, comparing data from different studies. [10] [11] [12] However, absolute half-lives should not be compared across studies because different assays, populations and statistical analysis methods all affect the absolute half-life observed. [13] [14] [15] To keep these variables constant, the International Society on Thrombosis and Haemostasis (ISTH), European Medicines Agency (EMA), and US Food and Drug Administration (FDA) guidance recommend studying a new rFVIII and a similar test product in the same individual. [16] [17] [18] These data can be used to calculate a half-life ratio (half-life of study product: half-life of comparator product) for valid comparison of PK parameters across different studies of different rFVIII products.
With several new options available, a better understanding of the potential benefits and limitations of rFVIII products could be gained through clear categorization of currently available EHL FVIII products.
Herein, we propose criteria for defining EHL rFVIII products, and then, we apply these parameters to assess which new rFVIII products are EHLs based on the available evidence from well-designed PK studies where a product is sequentially compared to a reference in the same individual.
| MATERIALS AND METHODS
This systematic review was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic reviews and MetaAnalyses) guideline. 19 Search and selection strategies were developed into a protocol and applied by an independent researcher to validate the results.
| Inclusion and exclusion criteria
Inclusion and exclusion criteria were developed to select for welldesigned PK comparator studies ( The relevance of each article or report identified during the search process was assessed by applying the inclusion and exclusion criteria and initially screening titles and abstracts to select publications for more further considerations.
| Data extraction and analysis
Data were extracted into a standardized electronic format, including study design, subject characteristics and numbers, and key PK data. Some of the included publications and government documents did not calculate half-life ratios, instead reporting only the absolute halflife in hours for the studied rFVIII and standard comparators. In these cases, a half-life ratio was calculated by dividing the half-life reported for the studied rFVIII product by that reported for the standard rFVIII control.
| RESULTS
In the literature screening, a total of 339 potentially relevant references were found, and 31 publications/reports/monographs (Table   S1 ) reporting on 11 studies were ultimately selected for qualitative analysis (some data were included in more than one source). Figure 1 depicts the study selection process. One PK study was subsequently excluded from the final analysis 20 because the product, BAY 79-4980, has been discontinued. The PK studies included in the final analysis are provided in Table 2 .
| Rational design: products intended to have extended half-life
Established methods that have been applied to extend the half-life of rFVIII include PEGylation-the chemical addition of a polyethylene glycol (PEG) to rFVIII 21, 22 -and Fc fusion-the covalent binding of rFVIII to the Fc domain of IgG 1 . 23 A novel approach to improve rFVIII PK characteristics is the formation of a "single-chain" by covalent binding of rFVIII heavy and light chains. 5, 24, 25 With more than 25 years of accumulated experience, PEGylation is a well-established technology for prolonging the half-life of proteins. 26 The technology has been used in twelve approved medicinal products since the 1990s and in more in development. 27, 28 In the case of rFVIII, 3 products (BAX 855, BAY 94-9027 and N8-GP) employ PEGylation, albeit with different size PEG molecules (Table 2) , to extend half-life by disrupting interactions with the low-density lipoprotein receptor-related protein (LRP) 1. This protein is responsible for the physiological clearance of FVIII; interfering with this interaction may lead to reduced hepatic clearance of rFVIII.
21,29
F I G U R E 1 Flow diagram depicting the search and selection process used to identify publications and reports on EHL FVIII products. *Additional data were obtained directly from Shire and Bayer in response to information requests, but this did not change the total number of PK studies included. The 31 records selected for further analysis are listed in Supplementary Information, Table S1 . EHL, extended half-life Fc fusion has been used to prolong the half-life of more than 300 therapeutic proteins in the last 25 years-either approved or in development. 30 The neonatal Fc receptor (FcRn) delays lysosomal degradation of Fc fusion proteins (and IgG) by cycling them back into circulation, thereby prolonging their plasma half-life. 30 Fc fusion technology is employed in the design of rFVIIIFc. 23 A different approach to improving PK characteristics was used in the design of rFVIII-SingleChain. The heavy and light chains of a truncated B-domain rFVIII were covalently bonded with the aim of improving rFVIII intrinsic stability and increasing its affinity for von
Willebrand factor (VWF). 31 Other new rFVIII products have been designed with different purposes other than to extend half-life ( 
| EHLs are not bioequivalent to standard rFVIII
Rationally, an EHL rFVIII should have enhanced PK characteristics that are significantly different from standard rFVIII. PK comparisons of exposure to different rFVIII products generally involve an assessment of the area under the curve (AUC) by calculating the ratio of one product to another. As part of the approval process for new rFVIII products, FDA and EMA assess bioequivalence by considering the 90% CIs of the ratio of the AUC for a new product in comparison with its parent compound or other relevant standard rFVIII. If the 90% CIs fall completely between 0.8 (80%) and 1.25 (125%), then the new product is considered bioequivalent to its parent molecule. 18, 36 Having any part of the 90% CI fall outside these limits is sufficient to conclude that a compound is not bioequivalent to 's comparator because there is 90% certainty that some individuals will have an AUC ratio that falls outside these bounds. We propose to use these bioequivalence limits to demonstrate the "biodifference" of EHL rFVIII products from standard. For an EHL FVIII, we would ideally expect the majority of individuals to have an AUC ratio above the limits of bioequivalence; if the 90% CIs for the AUC ratios fall completely above the window, then there is 90% certainty that the full range of AUC ratios obtained in the treated population will be biobetter than standard rFVIII. Figure 2 depicts the AUC ratio 90% CIs for new rFVIII products relative to this bioequivalence window. Human-cl rhFVIII has been shown to be bioequivalent to Kogenate FS as its 90% CIs for the AUC ratio are fully within the regulatory acceptance limits. 35 For rFVIII-SingleChain, the mean AUC ratio in comparison with Advate (1.35) falls close to the upper bioequivalence limit and the lower bound of the 90% CI extends well into the bioequivalence window. 25 Thus, while it cannot be concluded that rFVIII-SingleChain is bioequivalent to standard FVIII products, it can also not be concluded that there is 90% confidence that the full range of AUC ratios obtained in the treated population will be above the bioequivalence window. In contrast, the 90% CIs for AUC ratio for BAX 855 and the 95% CIs for AUC ratio for rFVIIIFc (90% CIs were not available during the preparation of the manuscript) fall completely above the 1.25 upper limit. The AUC ratios for these 2 products are
clearly not equivalent to those of standard FVIII. The results for N8-GP are compromised by the reporting of 95% CI rather than 90% CI and by the use of multiple comparator standard FVIIIs. 37 The lower limit of the 95% CI for the AUC ratio for N8-GP compared with a range of prestudy standard FVIII products is 1.23; the 90% CI would be higher and may well fall outside the bioequivalence window. 37 
| Demonstration of extended half-life and reduced clearance
According to ISTH guidance on study design for PK studies of coagulation factors such as rFVIII, 16 several criteria need to be met for appropriate comparison of their pharmacokinetics. Evidence is required from a PK comparator study wherein both products are tested in the same individual; therefore, the well-known phenomenon of individual differences observed in rFVIII half-lives 15 would not add variance to the calculated results. The relative comparison gained by taking the ratio of the absolute half-life of the study rFVIII to that of the stan dard rFVIII would cancel out the individual differences. Table 3 depicts the key studies included in this analysis that have a PK comparator design as described by the ISTH guidance. For BAX 855 and rFVIIIFc, where phase 1 and phase 2/3 studies fulfilled the criteria, the phase 2/3 study, with a larger sample size and as reported in the regulatory documents, is shown in Table 3 .
The available evidence from the studies included in this review suggests that rFVIII products designed to be EHLs and with AUC ratio 90% CIs that fall completely outside of the bioequivalence window have reduced clearance (Table 3) . However, the clearance data do not indicate a clear cut-off between EHL and standard rFVIII products that lends to a practical definition for an EHL rFVIII product based on this measure alone.
Similarly, as shown in Figure 3 , the data do not suggest a clear cutoff for the definition of an EHL FVIII based on half-life extension alone.
BAX 855 and rFVIIIFc, which have AUC ratio 90%/95% CIs that fall completely outside of the bioequivalence window, are among those with the largest half-life extension ratios, and Human-cl rhFVIII, which was bioequivalent to standard rFVIII based on AUC, has a lower halflife than the comparator product (ratio <1); however, the relationship between the AUC data and the half-life data for the other products is less clear. N8-GP demonstrated a relatively high half-life extension ratio. The half-life extension ratios for rFVIII-SingleChain and BAY 81-8973 (both LEOPOLD I- with VWF. 42, 43 While the FVIII interaction with VWF protects it from proteolytic degradation and binding to FVIII clearance receptors (LRP1), 44 it may also impose a biological limit to the time rFVIII can remain in circulation. 45 It is hypothesized that a substantial proportion of FVIII is cleared in a complex with VWF 43 and thus may limit the ability to extend the half-life of FVIII beyond that of VWF (median 15 hours; range 13-17 hours 23, 39 ). Therefore, the half-life extension for categorization as an EHL rFVIII needs to accommodate this limit but still be sufficient enough to ensure that, even with intra-and interperson variance in FVIII pharmacokinetics, 15 ,41 the F I G U R E 2 AUC ratio of study FVIII: control FVIII for included studies. All data are based on rFVIII measurements from chromogenic assays. Data are from individual clinical studies (as indicated) with different study designs and populations, so the results cannot be directly compared. Filled circles represent the mean (or † geometric mean), and bars represent the 90% or 95% confidence intervals (as indicated on the x-axes). The shaded box shows the bioequivalence limits specified by the FDA and EMA for AUC ratio 90% confidence intervals: 0.8 to 1.25. 18, 36 Dashed lines show where these limits fall on the panel with 95% confidence intervals, although it should be noted that they cannot be directly applied to 95% confidence interval data. *For N8-GP, multiple prior standard rFVIIIs were used as comparators in a single study. ‡ Additional data were obtained directly from Shire and Bayer in response to information requests. AUC, area under the curve majority of individuals can be protected from bleeds with a reduced dosing frequency. While some new rFVIII products may demonstrate some degree of mean half-life extension compared with standard FVIII, a small extension may not be sufficient to allow for at least an additional full day between doses. To further address this point, a separate modelling study has been carried out by a group including some of the authors of this review to identify the minimum half-life extension ratio required for a reduction in dosing frequency while maintaining the proportion of patients with plasma rFVIII levels above 1 IU/dL with no increase in the total weekly dose. 65 A pre- This review is meant to provide guidance to help physicians, patients and health funders to make informed choices when selecting rFVIII products. Ideally, the classification of standard vs EHL rFVIII products will provide better clarity regarding the rFVIII dosing intervals that can be expected to provide effective prophylaxis for the majority of individuals for the rFVIII products that we have discussed.
Towards this end, we recommend the development of a practical definition for EHL rFVIII products. Using the data available at the time of this review, we suggest that both AUC ratio and half-life ratio are needed to provide enough PK evidence to form a strong definition of EHL. Therefore, we propose a definition comprising 3 separate criteria:
1. Designed with technology to extend circulating biological half-life 2. Demonstration of difference from a standard rFVIII comparator for the majority of patients according to proposed "biodifference" criteria based on the lower limit of the 90% CI for the AUC ratio being above the FDA/EMA cut-off for bioequivalence (1.25 or 125%)
3.
Having a half-life ratio of 1.3 or higher, based on modelling.
65
T 35 AUC, area under the curve; CI, confidence interval; Chr, chromogenic assay; GMR, geometric mean ratio; OS, one-stage assay; SD, standard deviation; EHL, extended half-life. All results in this table are from chromogenic assays. Two phase 1 studies that reported data obtained using the one-stage assay are not included here (NCT01599819, BAX 855 and NCT01027377, rFVIIIFc) because data from phase 2/3 studies of the same FVIII products, obtained using the chromogenic assay, were available. For the products in development, BAY 94-9027 and N8-GP, limitations in the data because of study design and reporting differences make interpretation less straightforward; however, current evidence suggests that that they both fulfil criteria for EHL rFVIII. They are designed using a technology that has been established for extending half-life (definition criteria 1). Both products show evidence of halflife extension ratios greater than 1.3-fold, thereby meeting criteria 3.
The 50 IU/kg dose group of BAY 94-9027 met criteria 2. N8-GP may have met criteria 2 with 90% confidence intervals (only wider, 95%
confidence intervals are available) and/or comparison with a single standard rFVIII (multiple different comparators were used). As such, these agents should be classified as EHL rFVIII products despite the limitations imposed by different study designs and reporting.
This guidance provides a straightforward assessment of standard vs currently available EHL rFVIII products, which should ameliorate clinical decision-making regarding an initial approach for a patient.
Reduced dosing frequencies and maintenance of haemostatic efficacy of rFVIII products that meet the EHL definition should be possible for most patients. Given the great variance among individuals' PK responses, an individual's baseline terminal half-life, bleeding phenotype and physical activity level, as well as the rFVIII product half-life should be considered when deciding on an adequate prophylactic EHL rFVIII product dose and infusion schedule. 46 Importantly, classification of a concentrate can never substitute for careful clinical monitoring of patients, including measurement of rFVIII levels and PK profiles.
A limitation of this analysis is that not all products evaluated had data that allowed for a comparable application of our proposed criteria. There is considerable variation in study design, study population and data reporting that will certainly have influenced the results. As such, no clear comparative conclusions can be drawn.
A further limitation is the applicability of this analysis to children, who, in general, have higher clearance and shorter elimination halflives than adults. 15, 41 It might be expected that the half-life ratio between an EHL rFVIII and a standard FVIII would be the same in children and adults regardless of absolute half-life; however, there could potentially be differences dependent on the mechanism of half-life extension. At the time of writing, there are limited data on the PK characteristics of new rFVIII products in children (<12 years old). Once more evidence is available, a separate analysis should be
Half-life extension ratios of study FVIII: control FVIII for included studies. All data are based on rFVIII measurements from chromogenic assays. Data are from individual clinical studies (as indicated) with different study designs and populations, so the results cannot be directly compared. Filled circles represent the mean (or † geometric mean), and bars represent the 90% or 95% confidence intervals (as indicated on the x-axes), where available. Also, depicted is standard rFVIII half-life (1.0, line) and the half-life extension ratio above which modelling has shown that a meaningful reduction in the burden of infusions for an EHL rFVIII product (relative to a standard rFVIII) is possible without increasing rFVIII dose (1.3, dashed line) 65 . *Note that for N8-GP, multiple prior standard rFVIIIs were used as comparators in a single study. ‡ Additional data were obtained directly from Shire and Bayer in response to information requests.
§ No confidence intervals were available for Human-cl rhFVIII. EHL, extended half-life conducted for children. Furthermore, because the field is evolving rapidly, the definitions for adults and adolescents proposed in this review will need to be revisited as new products become available. 
| CONCLUSION
Having established an evidence-based definition for EHL rFVIII, these recommendations provide a framework for future assessments of rFVIII products. Furthermore, clarity regarding which rFVIII products fulfil EHL criteria supports rational and informed clinical decisions of physicians and patients when deciding on an EHL rFVIII product. A better understanding of these new tools in the armamentarium for management of severe haemophilia A could potentially enable better outcomes for patients.
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